HARVARD BIOSCIENCE INC HBIO
ASignal's systematic analysis rates HBIO as Neutral.
Reflects the latest available analysis · analyzed Nov 6, 2026
The case on HBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive revenue growth (11.1% YoY)
- Strong gross margin (58.16%) indicating pricing power
- Free cash flow positive at $5.30M
- Price near lower Bollinger Band suggesting potential mean reversion
- Forward P/E of 12.96x below market average
- Negative operating and net margins
- Negative return on equity (-89.95%)
- High debt-to-equity ratio (5.96x)
- MACD below signal line indicating weakening momentum
- Only one news source and no Reddit mentions, suggesting low market interest
See the full verdict on HBIO
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes HBIO
Most investors never get a second opinion, let alone several. ASignal runs HBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.